GENNIEFY
Market News
Latest financial news and analysis from global markets
GOOGL
Mark Cuban Upgrades TrumpRx to 'A-' — 'They're Doing A Good Job Actually' Says Denting Big Insurance Conglomerates Is A 'Win'
Mark Cuban isn't grading for style points—he's grading for impact. The billionaire co-founder of Cost Plus Drugs revisited TrumpRx and made clear what matters most: if it pressures the right players, it's working. From "B" To ‘A-' — Why The...
AMZN
Mark Cuban Upgrades TrumpRx to 'A-' — 'They're Doing A Good Job Actually' Says Denting Big Insurance Conglomerates Is A 'Win'
Mark Cuban isn't grading for style points—he's grading for impact. The billionaire co-founder of Cost Plus Drugs revisited TrumpRx and made clear what matters most: if it pressures the right players, it's working. From "B" To ‘A-' — Why The...
SBUX
Starbucks removes free drink perk customers may miss
Starbucks (SBUX) customers are accepting a lot more these days. The coffee giant revamped its rewards program, as Modern Retail reported, implemented new store-service protocols, explored pop-culture partnerships, and attempted to make its cafes seem welcoming again. Well, one incentive for ...
REGN
Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing?
Regeneron is seeing double-digit revenue growth and has more than 50 therapies in its pipeline, making it a good long-term investment.
AMGN
AMGN Q1 Deep Dive: Growth Drivers Offset Patent Losses, Pipeline Progress in Focus
Biotech company Amgen (NASDAQ:AMGN) announced better-than-expected revenue in Q1 CY2026, with sales up 5.8% year on year to $8.62 billion. The company expects the full year’s revenue to be around $37.8 billion, close to analysts’ estimates. Its non-GAAP profit of $5.15 per share was 8% above analysts’ consensus estimates.
GOOGL
Is Alphabet (GOOGL) Still Attractive After 136% Rally And AI Investment Surge
Some investors may be wondering whether Alphabet is starting to look expensive or still offers value, even after a strong run in its share price. The stock last closed at US$385.69, with returns of 12.0% over 7 days, 29.7% over 30 days, 22.4% year to date and 135.9% over the past year, which naturally raises questions about growth expectations and risk. Recent headlines have focused on Alphabet's ongoing investments in artificial intelligence and cloud services, as well as regulatory...
BAC
How The Tyson Foods (TSN) Investment Story Is Shifting As Analysts Rework Their Models
Tyson Foods just saw its modeled fair value trimmed from US$69.08 to US$68.54 per share, a small adjustment that still matters if you are watching the stock closely. That tweak comes as analysts remain split, with some highlighting sales momentum and others pointing to execution hurdles and valuation questions. Ahead, you will see how these shifting targets fit into the broader story and what to watch as the narrative continues to evolve. Analyst Price Targets don't always capture the full...
INTC
Spirit Ends Operations After White House Bailout Collapses
(Bloomberg) -- Spirit Aviation Holdings Inc. is winding down operations after the troubled US discount carrier buckled under the weight of surging fuel prices and a government bailout dangled by President Donald Trump fell through.Most Read from BloombergTrump Vows 25% Tariff on European Autos in Escalating Trade RiftSpirit Bailout Talks Said to Have Ended With Closure LoomingTrump Family-Backed Drone Firm Signs Weapons Deal With USTrump Rues State of Iran Talks, Says Prefers Not to StrikeTwo NJ
LMT
Villere St Denis Dumps 134,000 Tidewater (TDW) Shares Worth $9.3 Million
Specializing in offshore marine support, Tidewater serves global energy clients across oil, gas, and windfarm projects.
V
Villere St Denis Dumps 134,000 Tidewater (TDW) Shares Worth $9.3 Million
Specializing in offshore marine support, Tidewater serves global energy clients across oil, gas, and windfarm projects.
JPM
Villere St Denis Dumps 134,000 Tidewater (TDW) Shares Worth $9.3 Million
Specializing in offshore marine support, Tidewater serves global energy clients across oil, gas, and windfarm projects.
NVDA
Why Axsome Therapeutics Stock Jumped Over 20% in April
Axsome shares reached an all-time high last month, and there might be more to come.